Prostatype Genomics AB (PROGEN) AI Stock Analysis

Top Page

Prostatype Genomics AB

(Nasdaq OMX AB:PROGEN)

Select Model

Rating:42Neutral

Price Target:SEK 0.10▼(-3.74% Downside)

Action:reiterated

Date:09/30/26

The score is primarily constrained by weak financial performance—persistent large losses, negative margins, and sustained cash burn—despite some TTM revenue improvement. Technicals add pressure with a clear downtrend across moving averages and negative momentum, while valuation provides limited support due to a negative P/E and no dividend yield data.

Positive Factors

Focused precision-medicine businessThe company operates in a focused precision-medicine niche, using genomic and biomarker analysis to support prostate-cancer treatment decisions. A specialized diagnostic offering can create durable clinical relevance if adoption expands, because risk assessment and treatment guidance are recurring healthcare needs.

Negative Factors

Severe unprofitabilityDeeply negative gross, operating, and net margins show that current revenue does not cover the economics of the business. Unless pricing, delivery economics, or operating efficiency improve materially, persistent losses will constrain reinvestment and weaken the path to sustainable profitability.

Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 74.32M
Dividend Yield: ―
Average Volume (3M): 8.43M
Price to Earnings (P/E): -0.2
Beta (1Y): -0.24
Revenue Growth: 143.94%
EPS Growth: 70.95%
Country: Sweden
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Sc...

Prostatype Genomics AB Financial Statement Overview

Summary

Despite TTM revenue growth (+26.1% to ~1.0m), fundamentals remain weak: deeply negative gross margin (~-34%), large operating losses (~-66% margin), severe net losses (~-75% margin), and materially negative operating/free cash flow (~-20.9m/~-21.0m). Modest leverage helps, but ongoing losses and cash burn dominate the risk profile.

Income Statement

12Very Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.01M	594.00K	199.00K	1.36M	683.00K	10.00K
Gross Profit	-27.83M	-37.62M	1.92M	3.73M	683.00K	2.51M
EBITDA	-34.16M	-36.89M	-37.40M	-38.02M	-26.79M	-15.46M
Net Income	-37.90M	-44.50M	-41.05M	-41.44M	-29.09M	-15.63M
Balance Sheet
Total Assets	39.91M	50.86M	41.97M	49.22M	30.95M	40.20M
Cash, Cash Equivalents and Short-Term Investments	392.00K	9.07M	9.42M	2.68M	11.49M	20.33M
Total Debt	0	5.30M	67.00K	11.67M	867.00K	1.27M
Total Liabilities	33.36M	24.33M	8.50M	24.55M	4.80M	4.30M
Stockholders Equity	6.55M	26.53M	33.47M	24.67M	26.15M	35.91M
Cash Flow
Free Cash Flow	-20.96M	-24.06M	-52.57M	-37.70M	-27.69M	-18.58M
Operating Cash Flow	-20.90M	-23.80M	-44.71M	-29.14M	-27.69M	-16.08M
Investing Cash Flow	-12.27M	-13.36M	-8.36M	-8.57M	0	-2.50M
Financing Cash Flow	20.64M	36.83M	59.75M	28.91M	18.85M	23.05M

Prostatype Genomics AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.11

Price Trends

50DMA0.13Negative

100DMA0.15Negative

200DMA0.26Negative

Market Momentum

MACD-0.00Negative

RSI49.01Neutral

STOCH77.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Neutral. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.13, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.01 is Neutral, neither overbought nor oversold. The STOCH value of 77.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:PROGEN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:DVYSR	62Neutral	SEK 928.94M	59.78	―	―	6.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:QLINEA	51Neutral	SEK 282.34M	-1.13	-60.76%	―	33.26%	90.73%
SE:BIOVIC.B	45Neutral	SEK 103.68M	-1.44	-75.51%	―	56.06%	63.95%
SE:IMMNOV	43Neutral	SEK 33.70M	-0.30	-279.07%	―	31.66%	79.68%
SE:PROGEN	42Neutral	SEK 74.32M	-0.20	-229.18%	―	143.94%	70.95%
SE:ACARIX	33Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%

* Healthcare Sector Average

Performance Comparison

SE:PROGEN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:PROGEN	Prostatype Genomics AB	0.11	-0.12	-52.86%
SE:IMMNOV	Immunovia AB	0.05	-0.27	-84.28%
SE:QLINEA	Q-linea AB	14.90	-10.30	-40.87%
SE:ACARIX	Acarix AB	0.18	-0.10	-35.61%
SE:BIOVIC.B	Biovica International AB Class B	0.36	-0.14	-27.47%
SE:DVYSR	Devyser Diagnostics AB	55.00	-68.00	-55.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026

Prostatype Genomics AB AI Stock Analysis

Top Page